Search results - 5 results
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021
(2023) Keywords: Alpha COVID-19 Delta Vaccine effectiveness Health Topics: Acute respiratory tract infection Acute luchtweginfectie Infection respiratoire aiguë Service: Maladies virales Virale ziekten ...
Mycoplasma pneumoniae: delayed re-emergence after COVID-19 pandemic restrictions.
Mycoplasma and Chlamydia Infections (ESGMAC), and the ESGMAC Mycoplasma pneumoniae Surveillance (MAPS) study group Source: Lancet Microbe (2023) Health Topics: Acute respiratory tract infection Acute ...
Seasonal and inter-seasonal RSV activity in the European Region during the COVID-19 pandemic from autumn 2020 to summer 2022.
Publication Type: Peer reviewed scientific article Authors: Meslé, Margaux M I; Sinnathamby, Mary; Mook, Piers; WHO European Region Respiratory Network Group; Pebody, Richard; Lakhani, Anissa; ...
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022.
effectiveness (VE) in participating European countries since early 2021.AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients ≥ 20 years hospitalised with severe acute respiratory infection ...
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021.
SARS-CoV-2 in hospitalised severe acute respiratory illness (SARI) patients ≥ 20 years, combining data from these networks during Alpha (March-June)- and Delta (June-December)-dominant periods, ...